Agreement - September 14, 2021
Immunovia enters licensing agreement with JW BioScience
Immunovia has strengthened its patent protection for pancreatic cancer biomarkers by obtaining a global license from the South Korean company JW BioScience’s IP portfolio. The license agreement gives Immunovia global commercial rights for two biomarkers for early detection of pancreatic cancer. The biomarkers are also part of Immunovia, Inc.’s IMMray PanCan-d biomarker signature. Immunovia discovered […]
Intellectual Property - September 8, 2021
Diamyd Medical secures precision medicine patent
The European Patent Office has informed Diamyd Medical that the company’s patent application regarding prevention and treatment of autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene will be granted. The patent is valid until 2035 and provides central protection in Europe for the treatment or prevention of genetically defined autoimumune diabetes using GAD, which […]
Intellectual Property - September 1, 2021
Gedea Biotech granted US patent
Gedea Biotech has been granted a patent by the United States Patent and Trademark Office for the treatment of fungal infections by the company’s compound glucono-δ-lactone (GDL). The patent can be kept in force until 2037, states the company in a press release. “The US market for treatment of vaginal infections is worth at least […]
Biotech Business - July 28, 2021
Abera Bioscience receives US patent
The patent forms the basis of a new vaccine platform that the company has developed in parallel with existing platforms. The company has received a Notice of Allowance of its patent application “Fusion polypeptides comprising one or more inclusion body tags, methods and uses” by the US Patent Office. A new vaccine platform The new […]
Intellectual Property - April 28, 2021
Elicera Therapeutics files a patent application
Elicera Therapeutics has filed a patent application to protect the development of its drug candidate ELC-201. ELC-201 is the second oncolytic virus in Elicera Therapeutic’s product portfolio. It is based on an adenovirus that has been genetically modified in a way that makes the treatment applicable to most cancers and the patent application protects the […]
Intellectual Property - March 4, 2021
US court decision favors Symbicort in patent litigation
The US District Court for the Northern District of West Virginia has decided in favor of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva Drug Delivery, determining that asserted claims in three of AstraZeneca’s patents protecting Symbicort (budesonide/formoterol) in the US are not invalid. “AstraZeneca is pleased with the Court’s decision, and we maintain full […]
